A Therapy's Effect on Reduction of Exacerbations is the Attribute That Most Influences Physicians' Prescribing Decisions, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Novartis/Schering-Plough's indacaterol/mometasone will replace AstraZeneca's Symbicort as Decision Resources' proprietary clinical gold standard by 2012 for the treatment of asthma due to its once-daily dosing competitive advantage. In fact, because none of the therapies projected to launch within the next ten years are expected to offer advantages in efficacy over currently marketed long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations, Decision Resources' gold standard will be determined by incremental advantages in delivery, such as less-frequent daily dosing and a faster onset of action.
"Physicians we interviewed report that once-daily dosing has the potential to increase patient compliance. Patient compliance is important because asthma is a chronic disease that requires consistent administration of anti-inflammatory drugs to reduce disease severity and limit costly emergency healthcare," said Martin Quinn, analyst at Decision Resources.
The new report entitled Asthma: Emerging LABA/ICS Combinations Will Have a Difficult Time Differentiating Themselves from Existing Agents in the Class also finds that a therapy's effect on reducing exacerbations is the attribute that most influences physicians' prescribing decisions in asthma. Based on U.S. and European surveyed physicians, current and emerging therapies have no advantage over sales-leading GlaxoSmithKline's Advair/Seretide/Adoair on this attribute.
About the Report
Asthma: Emerging LABA/ICS Combinations Will Have a Difficult Time Differentiating Themselves from Existing Agents in the Class is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 email@example.com firstname.lastname@example.org
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved